Back to top

Analyst Reaffirms Buy on Harrow Health, Citing Expanding Ophthalmic Franchise and Long-Term Growth Pipeline

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on HROW stock, giving a Buy rating today. Lachlan Hanbury Brown has...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Harrow, Inc. (HROW)